Skip to main content

About

  • Our Organization
  • WHS Academic Alliance
  • Network

Events

  • Annual Summit
  • Regional Meetings
  • Other Events

Media

  • News
  • Press
  • Media Library
  • Newsletter
  • Imprint
  • Privacy Policy
2025
  1. Home
  2. —
  3. Program
  4. —
  5. WS 04 – Combating Antibiotic Resistance
WORKSHOPWS 04

Combating Antibiotic Resistance

The Role of Market Incentives in Europe for the Development of New Therapies

Date

Sunday, 12th October

Time

14:00-15:30 CEST

12:00-13:30 UTC

Room

Forum 2

Co-Host(s)

German Network against Antimicrobial Resistance (DNAMR)

Share this Page

About the session

Antimicrobial Resistance (AMR) is one of the biggest threats to global health. In the face of rapidly increasing resistance and a nearly exhausted antibiotic pipeline, it is crucial to establish innovative strategies to promote the development of new antimicrobials.

Within the European Union, solutions urgently need to be found in collaboration with all relevant stakeholders. While market incentives for new antibiotics are still being discussed in the European Union, the United Kingdom has already implemented a model. Targeted incentives are needed to motivate pharmaceutical companies to invest in the research and development of new antimicrobial agents.

Close cooperation between politics, science and industry is essential in order to develop sustainable and forward-looking models. As AMR is a global problem, coordinated action at national, European and international level is essential.
See all Sessions

Chair(s) / Moderator(s)

undefined undefined

Marc Gitzinger

BioVersys
CEO and Founder
Switzerland

Open

Speakers

undefined undefined

Takuko Sawada

Shionogi & Co., Ltd.
Director and Vice President of the Board
Japan

Open
undefined undefined

Dame Sally Davies

UK Special Envoy on Antimicrobial Resistance (AMR)
United Kingdom

Open
undefined undefined

Mathias W. Pletz

University Hospital Jena
Institute for Infection Medicine | Director
Germany

Open
undefined undefined

Dagmar Reitenbach

Federal Ministry of Health (BMG)
Medical Devices, Pharmacies, Narcotics | Deputy Director-General
Germany

Open
See all Sessions

Share this Page